LEONI, PIETRO
 Distribuzione geografica
Continente #
NA - Nord America 147
EU - Europa 138
AS - Asia 47
AF - Africa 8
Totale 340
Nazione #
US - Stati Uniti d'America 147
GB - Regno Unito 49
CN - Cina 25
SE - Svezia 23
IT - Italia 22
DE - Germania 12
SG - Singapore 10
IN - India 9
FR - Francia 8
IE - Irlanda 8
RU - Federazione Russa 5
EE - Estonia 4
TG - Togo 4
ZA - Sudafrica 4
CH - Svizzera 3
QA - Qatar 2
RS - Serbia 2
UA - Ucraina 2
JO - Giordania 1
Totale 340
Città #
Southend 47
Chandler 19
Fairfield 15
Houston 12
Seattle 11
Ashburn 9
Beijing 9
Woodbridge 9
Dublin 8
Princeton 8
Wilmington 7
Singapore 6
Bologna 5
Cambridge 5
Bremen 4
Lomé 4
Medford 4
Nanjing 4
Padova 4
San Diego 4
Turin 4
Westminster 4
Chicago 3
Ann Arbor 2
Changsha 2
Doha 2
Hebei 2
Redwood City 2
Saint Petersburg 2
Shenyang 2
Svilajnac 2
Amman 1
Bari 1
Castellammare di Stabia 1
Guangzhou 1
Jiaxing 1
Los Angeles 1
Mountain View 1
Nanchang 1
Ningbo 1
Norwalk 1
Poggio Renatico 1
Zhengzhou 1
Zurich 1
Totale 234
Nome #
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 92
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 90
Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408 87
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 79
Totale 348
Categoria #
all - tutte 908
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 908


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202067 0 3 0 4 8 5 11 11 8 3 8 6
2020/202134 9 3 0 0 2 2 1 2 7 3 1 4
2021/202270 4 0 3 5 7 5 0 7 6 4 17 12
2022/202380 5 6 5 10 8 7 2 10 16 5 6 0
2023/202419 1 3 1 2 1 0 5 0 3 0 2 1
2024/202514 7 7 0 0 0 0 0 0 0 0 0 0
Totale 348